Currently, the optimal sequential use of androgen receptor (AR) axis-targeted agents and taxane chemotherapies remains undetermined. We aimed to elucidate the resistance status between taxanes and enzalutamide, and the functional role of the AR axis. Enzalutamide-resistant 22Rv1 cells showed collateral resistance to taxanes, including docetaxel and cabazitaxel. However, taxane-resistant cells showed no collateral resistance to enzalutamide; taxane-resistant cells expressed comparable protein levels of full-length AR and AR variants. Knockdown of both full-length AR and AR variants rendered cells sensitive to taxanes, whereas knockdown of AR variants sensitized cells to enzalutamide, but not to taxanes. In contrast, overexpression of full-length AR rendered cells resistant to taxanes. Consistently, the prostate-specific antigen response and progression-free survival in docetaxel chemotherapy were worse in cases with prior use of ARAT agents compared with cases without. Collateral resistance to taxanes was evident after obtaining enzalutamide resistance, and aberrant AR signaling might be involved in taxane resistance.
| INTRODUCTION
Currently, androgen-deprivation therapy (ADT) with or without upfront docetaxel or abiraterone is the standard treatment for metastatic prostate cancer. [1] [2] [3] Although most prostate cancers are dependent on androgens for tumor growth and respond prominently to ADT, they eventually overcome low circulating levels of androgens and progress in a castration-resistant manner, despite consecutive ADT. Taxanes including docetaxel and cabazitaxel are chemotherapeutic agents that confer a survival benefit to patients with castration-resistant prostate cancer (CRPC). In addition to taxanes, the radioisotope radium-223 and novel androgen receptor (AR) axistargeted (ARAT) agents including the CYP17 inhibitor abiraterone and antiandrogen enzalutamide have shown tremendous benefits, including survival in patients with CRPC, in clinical trials. [4] [5] [6] [7] [8] [9] [10] [11] Thus, multiple agents are currently available for the treatment of CRPC, mainly in a sequential manner. However, there is scarce evidence on their sequential use; therefore, optimal sequential use of ARAT agents and taxane chemotherapies remains undetermined. 12 To date, various cross-or collateral resistance among those agents has been reported. Several studies have consistently shown robust cross-resistance between enzalutamide and abiraterone in both preclinical and clinical studies. 13 Similarly, collateral partial resistance to cabazitaxel in docetaxel-resistant cells was also reported in
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a preclinical study. 14 In addition, van Soest et al 15 have reported collateral resistance to docetaxel and cabazitaxel in enzalutamide-resistant cells in an in vitro experiment, but not to cabazitaxel in an in vivo experiment. 16 Conversely, Al Nakouzi et al 17 have reported no collateral resistance to cabazitaxel in enzalutamide-resistant tumors, and no collateral resistance in cabazitaxel-resistant cells to abiraterone or enzalutamide. However, there are no reports on cellular resistance to ARAT agents in docetaxel-resistant cells.
Thus, there are controversial or unreported findings on the resistance status between taxanes and ARAT agents. In addition, aberrant AR signaling by ligand-dependent activation of full-length AR and ligand-independent activation of AR variants lacking a ligand-binding domain and exerting constitutive activation without the ligand has been suggested as playing a critical role in cross-or collateral resistance among agents for CRPC. 18 Therefore, in this study, we aimed to elucidate the resistance status between taxanes and enzalutamide, as well as the functional role of the AR axis in the resistance status between taxanes and enzalutamide using CRPC 22Rv1 cells, which express both full-length AR and AR variants. 
| MATERIALS AND METHODS

| Cell culture
| Antibodies and reagents
Antibodies against AR (N-20, sc-816) and β-actin (A3854) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and Sigma (St. Louis, MO, USA), respectively. Enzalutamide was purchased from Selleck Chemicals (Houston, TX, USA).
| Knockdown analysis using siRNAs
The following double-stranded RNA oligonucleotides were commercially generated by Thermo Fisher Scientific: 5′-CAUAGUGACACCC AGAAGCUUCAUC-3′ (sense) and 5′-CCGUAACCAUUAUAGACGCU AUCCA-3′ (antisense) for AR #1; 5′-UAGAGAGCAAGGCUGCAAAGG AGUC-3′ (sense) and 5′-GACUCCUUUGCAGCCUUGCUCUCUA-3′
(antisense) for AR #2; and 5′-GUAGUUGUGAGUAUCAUGATT-3′
(sense) and 5′-UCAUGAUACUCACAACUACTT-3′ (antisense) for AR V7. 22Rv1 cells were transfected with siRNA (40 nmol/L for AR #1
and AR #2; 5 nmol/L for AR V7) using Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer's protocol.
| Plasmid construction and stable transfectants
The AR-GFP plasmid was kindly provided by Dr. Toshihiko Yanase (Fukuoka University, Fukuoka, Japan). 21 
| Western blot analysis
Whole-cell extracts were prepared as described previously. 19, 20, [22] [23] [24] The bound antibodies were visualized using an ECL kit (GE Healthcare Bio-Sciences, Piscataway, NJ, USA), and images were obtained using an image analyzer (Ez-Capture MG; ATTO, Tokyo, Japan).
| Cytotoxicity analysis
Cytotoxicity analyses were carried out as described previously. 19, 20, [22] [23] [24] 
| Cell proliferation assay
The cell proliferation assay was carried out as described previously. 19, 20 Briefly, 22Rv1 cells (2. computed tomography, MRI, and bone scan. 25 Extent of disease on bone scan score was determined according to a previous report. 26 Prostate-specific antigen (PSA) doubling time was calculated as described previously. 27 Progression was defined according to consecutive PSA increments resulting in 25% increases and 2 ng/mL over the nadir despite consecutive ADT, or progression of soft-tissue lesions or the appearance of two lesions on a bone scan. 
| RESULTS
| Resistance status between taxanes and enzalutamide, and expression level of full-length AR and AR variants in taxane-resistant cells
First, the resistance status between taxanes and enzalutamide was examined using enzalutamide-resistant and docetaxel-resistant 22Rv1 cells, 19, 20 as well as cabazitaxel-resistant 22Rv1 cells established in this study ( Figure 1A ). As shown in Figure 1B , taxane-resistant cells showed no collateral resistance to enzalutamide. However, enzalutamide-resistant cells showed significant resistance to taxanes, including docetaxel and cabazitaxel ( Figure 1C ).
To explore the mechanism of no collateral resistance in taxaneresistant cells to enzalutamide, the expression of full-length AR and AR variants was investigated in parental and taxane-resistant cells.
Although full-length AR expression at the mRNA level was downregulated in docetaxel-resistant cells, AR V7 mRNA was comparable between parental and resistant cells (Figure 2A) . However, at the protein level, the expression level of both full-length AR and AR variants were comparable between parental and docetaxel-resistant cells ( Figure 2B ). Conversely, although full-length AR expression at the mRNA level was upregulated in cabazitaxel-resistant cells, AR V7 mRNA was comparable ( Figure 2C ). However, at the protein level, the expression level of both full-length AR and AR variants were comparable between parental and cabazitaxel-resistant cells (Figure 2D ). In contrast, enzalutamide-resistant 22Rv1 cells expressed increased mRNA and protein levels of both full-length AR and AR variants, as shown previously. 
| Effect of AR signaling on cell proliferation and cellular resistance to taxanes and enzalutamide
To explore the role of full-length AR and AR variants in resistance to taxanes and enzalutamide, we examined cellular sensitivity to taxanes and enzalutamide when AR expression was downregulated using two kinds of AR-specific siRNAs (AR siRNA #1 and #2). As shown in Figure 3A , AR siRNA #1 targeting exon 4 successfully sup- 19,21 Thus, we used siRNAs specific to AR V7. 29 As shown in Figure 4A , the expression of AR variants was suppressed by AR V7-specific siRNA. However, cell proliferation was not significantly suppressed by AR V7-specific siRNA, which could be due to the compensation of suppressed AR variants by full-length AR (Figure 4B) . Similarly, cellular sensitivities to taxanes, including docetaxel and cabazitaxel, were comparable when AR V7-specific siRNA was Table 1 , which shows similar clinicopathological characteristics between cases with and without prior use of ARAT agents. Prostate-specific antigen response, defined as >50% PSA decline, was recognized in 2 (20.0%) and 16 cases (28.1%) with or without prior use of ARAT agents, respectively. As shown in Figure 6A , PSA declines were significantly lower in cases with prior use of ARAT agents compared with cases without prior use of ARAT agents (P = .047). Similarly, progression-free survival was significantly shorter among cases with prior use of ARAT agents compared with cases without prior use of ARAT agents (P = .019) ( Figure 6B ).
| DISCUSSION
This study showed collateral resistance to taxanes, including doc- cabazitaxel. In that study, there was no collateral resistance to cabazitaxel in an in vivo experiment, in which PC346C cells were shown to express full-length AR, but it remains unknown whether AR variants were expressed. 16 In addition, Al Nakouzi et al 17 showed
no collateral resistance to cabazitaxel in LNCaP-derived enzalutamide-resistant cells established in an in vivo system. Thus, there
were controversial results, and collateral resistance to cabazitaxel in enzalutamide-resistant cells could be dependent on the cell-line type or cellular context. However, there was no collateral resistance to enzalutamide in taxane-resistant cells, which is exactly compatible with the study by Al Nakouzi et al, 17 which showed no collateral resistance to enzalutamide in cabazitaxel-resistant 22Rv1 cells.
Androgen receptor variants are a critical factor affecting cellular sensitivity to ARAT agents, including enzalutamide. 18 Consistently, this study clearly showed that knockdown of AR variants, but not knockdown of full-length AR, successfully enhanced cellular sensitivity to enzalutamide. In addition, this study showed for the first time that suppression of both full-length AR and AR variants exerted augmented cellular sensitivity to taxanes, whereas the suppression of either full-length AR or AR variants showed no effect on cellular resistance to taxanes. Similarly, we have previously anes through various mechanisms. 35 However, there is a limitation that only cells derived from a single cell line were utilized in this study.
F I G U R E 5
Effects of androgen receptor (AR) overexpression in 22Rv1 cells and of AR knockdown in enzalutamide-resistant 22Rv1 cells on cellular resistance to taxanes. A, Whole-cell extracts from stable transfectants of 22Rv1 cells with AcGFP and AR-GFP plasmids were subjected to SDS-PAGE, followed by western blotting for the indicated proteins. B, Stable transfectants of 22Rv1 cells with AcGFP and AR-GFP plasmids were seeded in 96-well plates. On the following day, 10 nmol/L docetaxel or 2.5 nmol/L cabazitaxel was applied. After 48 hours, the cell survival rates were analyzed by cytotoxicity analyses. Cell survival when transfected with AcGFP plasmid was defined as 1. Boxes, mean; bars, ±SD. *P < .05 (compared with AcGFP plasmid). C, 22Rv1/MDV cells were transfected with 40 nmol/L of the indicated siRNA and seeded in 96-well plates. On the following day, 10 nmol/L docetaxel or 2.5 nmol/L cabazitaxel was applied. After 48 hours, the cell survival rates were analyzed by cytotoxicity analyses. Cell survival when transfected with control siRNA was defined as 1. Boxes, mean; bars, ±SD. *P < .05 (compared with control siRNA)
Several studies have suggested that taxanes exert a cytotoxic effect through impairment of AR signaling because taxane treatment decreases cellular AR activity by inhibiting total AR as well as AR variants. [36] [37] [38] However, taxanes at low concentrations have recently shown no impact on AR localization, indicating taxanes do not act through AR. 39 In addition, Al Nakouzi et al 17 have
clearly shown that AR suppression is not a cause but a result of cell death by taxanes. Thus, although there is controversy, the results showing that the suppression of AR signaling augments taxane toxicity support the hypothesis that AR inhibition by taxanes is not a cause of cytotoxicity by taxanes but a result of taxane cytotoxicity.
Aberrant AR signaling was suggested to promote taxane resistance. However, it has been shown that AR V7 expression in circulating tumor cells was not a predictive factor in taxane chemotherapy, 40, 41 contrary to that in ARAT agents. 42 This suggests that AR V7 causing incomplete suppression of AR signaling in ADT is not involved in the efficacy of taxane chemotherapy. However, both studies in taxane chemotherapy were regrettably carried out after treatment with enzalutamide and/or abiraterone in most patients. 40, 41 In this setting, however, aberrant AR signaling promoting resistance to ARAT agents already exists, even in cases with no AR V7 expression, making AR V7 an unreliable parameter of aberrant AR signaling. Expression of AR V7 promoting cellular resistance to ARAT agents as well as taxanes was shown to increase after treatment with ARAT agents, but not after taxane chemotherapy, 43 suggesting that taxane chemotherapy is less effective after treatment using ARAT agents, but not vice versa.
Consistently, the clinical data suggested less sensitivity to docetaxel after ARAT agents, although this study might be biased by long recruitment periods and lead time. Several retrospective studies have shown an inferior response to taxane chemotherapies in cases previously treated with ARAT agents compared with cases without pre-ARAT agents, which is similar to this study's results. [44] [45] [46] Conversely, worse responses to ARAT agents after taxane 54, 55 In CRPC refractory to ARAT agents, a novel therapeutic method that blocks ligand-independent AR signaling, in combination with taxanes, would be required to improve the therapeutic outcome. In a preclinical study, a novel antiandrogen agent, EPI, which binds to the N-terminal domain of AR and inhibits AR variants in addition to full-length AR, showed prominent antitumor activity in combination with docetaxel for 22Rv1-xenograft tumors. 56 Taken together, this study has shown that collateral resistance to taxanes was established after obtaining enzalutamide resistance.
Thus, it has been suggested that prior use of taxanes before ARAT agents for hormone-naïve prostate cancer and CRPC could be more advantageous, although it should be examined in clinical trials in the future. Augmented aberrant AR signaling might also be involved in taxane resistance, notably suggesting that comprehensive inhibition of AR signaling might augment cellular sensitivity to taxanes. These findings support upfront use of taxanes for castration-sensitive prostate cancer before aberrant AR signaling emerges, as well as combination therapy of taxanes with ARAT agents or novel agents inhibiting aberrant AR signaling for CRPC. Research. We are grateful to Dr. Toshihiko Yanase (Fukuoka University, Fukuoka, Japan) for providing the AR-GFP expression plasmid.
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